David J. Woodhouse - 29 Dec 2021 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role: Chief Executive Officer, Director
Signature: /s/ Valerie Pierce, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 29 Dec 2021
Net transactions value: +$137,989
Form type: 4
Filing time: 30 Dec 2021, 16:09:25 UTC
Previous filing: 19 Nov 2021
Next filing: 04 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGM	Common Stock	Options Exercise	$100,000	+12,987		$7.70	12,987	29 Dec 2021	Direct
transaction	NGM	Common Stock	Options Exercise	$37,989	+4,667	+36%	$8.14	17,654	29 Dec 2021	Direct
holding	NGM	Common Stock						80,000	29 Dec 2021	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGM	Stock Option (Right to Buy)	Options Exercise	$0	-12,987	-13%	$0.000000	87,013	29 Dec 2021	Common Stock	12,987	$7.70	Direct	F2
transaction	NGM	Stock Option (Right to Buy)	Options Exercise	$0	-4,667	-7.5%	$0.000000	57,833	29 Dec 2021	Common Stock	4,667	$8.14	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares held by The Woodhouse Family Trust 9/8/05.
F2	Fully vested.
F3	The shares subject to the stock option are early exercisable and vest over a four-year period commencing January 1, 2018, with 1/48th of the shares vesting on a monthly basis.